8 results
425
CTCX
Carmell Corp - Ordinary Shares
6 Jul 23
Business combination disclosure
5:15pm
that assure lot-to-lot clinical setting consistency including 3 potency assays No need to train staff in PRP extraction Novel cross-linker to drive … , Share & Trends Analysis Report By Procedure (Follicular Unit Extraction, Follicular Unit Transplantation), By Therapy (Low-level Laser Therapy, Stem
8-K
EX-99.1
CTCX
Carmell Corp - Ordinary Shares
6 Jul 23
Other Events
5:11pm
consistency including 3 potency assays No need to train staff in PRP extraction Novel cross-linker to drive sustained release of growth factors Lower … By Procedure (Follicular Unit Extraction, Follicular Unit Transplantation), By Therapy (Low-level Laser Therapy, Stem Cell Hair Restoration, Platelet-rich Plasma
424B3
CTCX
Carmell Corp - Ordinary Shares
23 Jun 23
Prospectus supplement
4:47pm
considered Carmell’s Phase 2-stage biotechnology platform with multiple product candidates designed to be: (a) allogeneic, with no need for (i) extraction … candidates designed to be: (a) allogeneic, with no need for (i) extraction of whole blood from patients, (ii) capital equipment to harvest biomaterials
- Prev
- 1
- Next